Loading...
Loading...
Jefferies reiterates its Buy rating and $17 target price on Optimer Pharmaceuticals
OPTR as the company preannounces in-line 4Q sales for Dificid.
Jefferies says, "Preannounced Dificid 4Q11 gross sales of $12.2M (~$10.6M net sales) were in-line with our/cons estimates of $10.9M/$11.2M net sales, respectively. With strong initial U.S. launch uptake of Dificid and expected EU launch in ~2Q12 by partner Astellas, triggering ~$65M milestone, we view OPTR current valuation as attractive."
OPTR closed at $11.93 per share on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in